82 results
8-K
EX-99.1
ABSI
Absci Corp
14 May 24
Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results
7:32am
)
Interest expense
Other income, net
Total other income, net
Loss before income taxes
Income tax expense
Net loss per share:
Basic and diluted
Weighted …
Deferred tax liability, net
Deferred revenue, long-term
Other long-term liabilities
TOTAL LIABILITIES
STOCKHOLDERS' EQUITY
Preferred stock, $0.0001 par
ARS
2024 FY
ABSI
Absci Corp
23 Apr 24
Annual report to shareholders
4:10pm
product for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver … risks, including intellectual property, regulatory laws, local laws, tax and accounting. To finance any acquisitions or asset purchase, we may choose
8-K
EX-99.1
47na wej1ap3an90e4
21 Mar 24
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
7:31am
8-K
EX-1.1
3vivp4ca nq11amflxfk
28 Feb 24
Absci Announces Proposed Public Offering of Common Stock
4:06pm
424B5
2sfma
28 Feb 24
Prospectus supplement for primary offering
8:34am
424B5
cdhhz
27 Feb 24
Prospectus supplement for primary offering
4:40pm
8-K
EX-99.1
3cnmulu7slckds 8554
14 Nov 23
Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results
4:40pm
8-K
EX-99.1
4f2b6
14 Aug 23
Absci Reports Business Updates and Second Quarter 2023 Financial and Operating Results
8:13am